<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684277</url>
  </required_header>
  <id_info>
    <org_study_id>SF2020-2-4113</org_study_id>
    <nct_id>NCT04684277</nct_id>
  </id_info>
  <brief_title>Internet-Based Interventions for MDD</brief_title>
  <official_title>Effectiveness of Internet-Based Interventions for Treatment Compliance and Outcomes of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The acute and remission depression patients of 18-65 years old were recruited. At the time of&#xD;
      enrollment, the demographic, symptomatic, neuropsychological and medication adherence data&#xD;
      was collected. After the completion of the baseline assessment and examination, the patients&#xD;
      were given antidepressant treatment or antidepressant treatment combined with Internet-based&#xD;
      interventions. Clinical evaluation was performed at 1, 3 months (acute patients) and 6, 12&#xD;
      months (remission patients) after treatment, including the medication adherence, therapeutic&#xD;
      efficacy, recurrence rate and functional rehabilitation. Through above work, this research is&#xD;
      expected to provide clinicians with a set of Internet generalized technologies to improve the&#xD;
      compliance and clinical outcomes of patients with depression, and to provide patients with&#xD;
      treatment and management of the entire disease cycle.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAMD17 reduction ratio</measure>
    <time_frame>3 months</time_frame>
    <description>The difference of HAMD17 reduction ratio between the two groups was compared</description>
  </primary_outcome>
  <primary_outcome>
    <measure>recurrence rate</measure>
    <time_frame>12 months</time_frame>
    <description>The difference of recurrence rate between the two groups was compared</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Depression</condition>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>antidepressant treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recieve antidepressant treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antidepressant treatment combined with Internet-based interventions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recieve antidepressant treatment combined with Internet-based interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antidepressant treatment</intervention_name>
    <description>depression recieve antidepressant treatment</description>
    <arm_group_label>antidepressant treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>antidepressant treatment combined with Internet-based interventions</intervention_name>
    <description>depression recieve antidepressant treatment combined with Internet-based interventions</description>
    <arm_group_label>antidepressant treatment combined with Internet-based interventions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-65 years old, acute (HAMD17 &gt; 17) and remission (HAMD17 &lt; 8) depression&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other mental illnesses, serious somatic illnesses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tianmei Si, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of mental health, Peking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunai Su, MD</last_name>
    <phone>8610-62352880</phone>
    <email>suyunai@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jitao Li, MD</last_name>
    <phone>8610-82801960</phone>
    <email>ljt_102124@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yunai Su</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunai Su</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Si Tianmei</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

